PNT2002 is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PSMA is overexpressed in the vast majority of prostate cancers (>85%), but very limited to normal tissues. Every year in the United States 52,000 men are either diagnosed with or progress to, mCRPC.
PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177. POINT has developed a unique radioactive API as well as formulation intellectual property for PNT2002.
Lantheus and POINT Biopharma have announced a strategic collaboration and exclusive license agreements for the commercialization of PNT2002.
PNT2002 is currently in the randomization stage of its Phase 3 study designed to evaluate superiority to the standard of care in mCRPC patients - learn more about the study at https://www.splashtrial.com.